Perspective Therapeutics (CATX) Goodwill (2023 - 2024)
Perspective Therapeutics' (CATX) quarterly Goodwill came in at $24.1 million in Q3 2024, down 11.78% year-over-year from $27.3 million in Q4 2023, and little changed quarter-over-quarter from $24.1 million in Q2 2024.
Analysis
Perspective Therapeutics (CATX) Goodwill (2023 - 2024) Analysis & Trends
Perspective Therapeutics has disclosed Goodwill across 2 years of filings, most recently posting $24.1 million for Q3 2024.
- In Q3 2024, Goodwill fell 11.78% year-over-year to $24.1 million; the TTM figure through Sep 2024 stood at $24.1 million (down 11.78% YoY), while the FY2023 annual figure was $24.1 million, changed N/A from the prior year.
- Goodwill came in at $24.1 million for Q3 2024 at Perspective Therapeutics, roughly flat from $24.1 million in the prior quarter.
- In the past five years, Goodwill ranged from a high of $27.3 million in Q1 2023 to a low of $24.1 million in Q4 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn |
| 10 | Perspective Therapeutics | 361.95 Mn | 361.95 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2024 | 24.10 Mn |
| Jun 30, 2024 | 24.10 Mn |
| Mar 31, 2024 | 24.10 Mn |
| Dec 31, 2023 | 24.10 Mn |
| Sep 30, 2023 | 27.32 Mn |
| Jun 30, 2023 | 27.32 Mn |
| Mar 31, 2023 | 27.32 Mn |